Lately, it has been reported that, in non-diabetic post-menopausal osteoporotic women with primary hyperparathyroidism, the administration of PTH (1–84) reduces basal blood glucose and this effect can be mediated by changes in serum OC levels rather than PTH-induced glucose uptake by peripheral tissues [74]. The gene discussed is PTH; the disease is primary hyperparathyroidism.